At the time of writing, Strata Critical Medical Inc [SRTA] stock is trading at $4.9, up 8.17%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SRTA shares have gain 21.59% over the last week, with a monthly amount glided 18.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Strata Critical Medical Inc [NASDAQ: SRTA] stock has seen the most recent analyst activity on February 26, 2025, when Lake Street initiated its Buy rating and assigned the stock a price target of $6.50. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on July 18, 2023, and set its price target to $13. On July 17, 2023, Ladenburg Thalmann initiated with a Buy rating and assigned a price target of $13 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $14 on September 28, 2021. JP Morgan initiated its recommendation with a Overweight and recommended $16 as its price target on September 09, 2021. Deutsche Bank started tracking with a Buy rating for this stock on September 01, 2021, and assigned it a price target of $15. In a note dated August 26, 2021, Credit Suisse initiated an Outperform rating and provided a target price of $14 on this stock.
For the past year, the stock price of Strata Critical Medical Inc fluctuated between $2.35 and $5.17. Strata Critical Medical Inc [NASDAQ: SRTA] shares were valued at $4.9 at the most recent close of the market.
Analyzing the SRTA fundamentals
According to Strata Critical Medical Inc [NASDAQ:SRTA], the company’s sales were 254.34M for trailing twelve months, which represents an 4.20% jump.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Strata Critical Medical Inc [NASDAQ:SRTA] has a current ratio of 5.95. Further, the Quick Ratio stands at 5.95. Considering the valuation of this stock, the price to sales ratio is 1.57, the price to book ratio is 1.79.
Transactions by insiders
Recent insider trading involved Tomkiel Melissa M., President and General Counsel, that happened on Aug 04 ’25 when 47995.0 shares were sold. Chief Financial Officer, Heyburn William A. completed a deal on Aug 04 ’25 to sell 46918.0 shares. Meanwhile, Officer MELISSA TOMKIEL bought 47995.0 shares on Aug 04 ’25.
